Company: PRTA
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001559053-25-000009
Chunk: 147

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-02-27
Form: 10-K
Item: Item 7
Chunk 147
---
4 (in thousands):

Total2025202620272028ThereafterOperating leases (1)$12,129 $3,179 $3,158 $3,269 $2,523 $— Purchase obligations (2)12,729 12,633 96 — — — Contractual obligations under license agreements274 64 60 60 45 45 Total$25,132 $15,876 $3,314 $3,329 $2,568 $45 

(1) See Note 6, “Commitments and Contingencies” to our Consolidated Financial Statements.

(2) Purchase obligations as of the filing date includes additional $2.1 million purchase commitments to our contract manufacturers.

In addition to the contractual obligations above, we also expect to have future material cash requirements related to our clinical trials, discovery and pre-clinical programs, human capital and intellectual property. Assuming no significant change in our business, we expect the full year 2025 net cash used in operating and investing activities to be approximately $168 million to $175 million.